{"entity":{"id":"nct05645692","kind":"trial","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","aka":[],"tldr":"A phase 2 trial of Atezolizumab and Tiragolumab in bladder & urothelial cancer, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer is a phase 2 interventional study registered as NCT05645692 by Hoffmann-La Roche, with 204 participants enrolled, started 2023-04-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Atezolizumab, Tobemstomig and Tiragolumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05645692","url":"https://clinicaltrials.gov/study/NCT05645692"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","tigit-blockade"],"targets":[],"drugs":["atezolizumab","tiragolumab"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05645692","phase":"2","setting":"A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT05645692","source":"https://clinicaltrials.gov/study/NCT05645692","fetchedAt":"2026-10-07T16:53:48.601Z","studySha256":"c498f4a3027b6baf17b45b7932440740cda1019d74d28a8ef648a6264c3cedf7","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-28","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":204,"enrolmentType":"ACTUAL","siteCount":56,"recruitingSiteCount":0,"countries":["Australia","Brazil","China","Denmark","France","Germany","Greece","Italy","Mexico","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-04-13","startedType":"actual","enrolled":204,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05645692/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}